Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.
The efficacy of intravenous chemotherapy for breast cancer has been improving with newer agents. However, the fractional improvements in breast cancer progression-free survival were quite modest and these small gains are obtained at the cost of significant toxicity. To address this problem, paclitaxel solid dispersion (PSD), a Cremophor EL-free formulation prepared by supercritical antisolvent process using hydrophilic polymers as carrier, was developed to avoid Cremophor EL-associated toxicities in Taxol(®). In this study, we investigated the antitumor activity of PSD as a function of dose from 12 to 24mg/kg (dose-effect) and compared antitumor activity of 18mg/kg dose of PSD to that of Taxol(®) (relative efficacy) in female athymic mice bearing mammary tumor xenografts. In dose-effect study, PSD showed excellent activity and good tolerance at all doses tested with a significant increase in tumor growth inhibition, recurrence time, survival percent, and number of tumor free survivors compared to control (P<0.01). In all of the four doses tested in this study, the magnitude of the increase in effectiveness of PSD was quite substantial and statistically significant with similar degrees of weight loss. In relative efficacy study of PSD and Taxol(®), PSD demonstrated a greater degree of tumor growth inhibition with 10 complete tumor regressions (100%) and eight tumor-free survivors (80% cure). Besides, mice treated with PSD regained their initial body weight by day 27 following initial acute weight reductions, whereas mice treated with Taxol(®) required more than 40 days to regain their initial weight. In conclusion, PSD prepared by supercritical process was very effective and safe, without Cremophor EL-associated toxicities of Taxol(®), in human mammary tumor xenografts with possibilities of dose escalation.
Shanmugam
Srinivasan
S
Pharm. R&D Institute, Hanmi Pharm. Co., Ltd., Hwasung, Gyeonggi, Republic of Korea.
Park
Jae-Hyun
JH
Chi
Sang-Cheol
SC
Yong
Chul Soon
CS
Choi
Han-Gon
HG
Woo
Jong Soo
JS
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000737:chemistry; D004339:Drug Compounding / Q000379:methods*; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D008819:Mice, Nude; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D017239:Paclitaxel